These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 12593383)
21. Appropriate use of nevirapine for long-term therapy. Leith J; Piliero P; Storfer S; Mayers D; Hinzmann R J Infect Dis; 2005 Aug; 192(3):545-6; author reply 546. PubMed ID: 15995971 [No Abstract] [Full Text] [Related]
22. Top stories of 2008. Antiretroviral rollout--successes and challenges. Friedland GH AIDS Clin Care; 2009 Jan; 21(1):5. PubMed ID: 19219959 [TBL] [Abstract][Full Text] [Related]
23. Antiretroviral rounds. Putting resistance to work. Daar ES; Elion R AIDS Clin Care; 2004 Jul; 16(7):56, 60. PubMed ID: 15300926 [No Abstract] [Full Text] [Related]
24. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884 [TBL] [Abstract][Full Text] [Related]
26. Anti-HIV agents. Atazanavir as a booster for protease inhibitors. TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850 [No Abstract] [Full Text] [Related]
27. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ; Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040 [TBL] [Abstract][Full Text] [Related]
28. Complications and side effects. Minimizing fat loss--comparing nukes. TreatmentUpdate; 2007; 19(5):6. PubMed ID: 17955615 [No Abstract] [Full Text] [Related]
29. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption. Barreiro P; de Mendoza C; González-Lahoz J; Soriano V Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992 [TBL] [Abstract][Full Text] [Related]
30. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. Canestri A; Ghosn J; Wirden M; Marguet F; Ktorza N; Boubezari I; Dominguez S; Bossi P; Caumes E; Calvez V; Katlama C Antivir Ther; 2006; 11(5):561-6. PubMed ID: 16964823 [TBL] [Abstract][Full Text] [Related]
31. Complications and side effects. Bone changes after starting HAART. TreatmentUpdate; 2007; 19(5):6-7. PubMed ID: 17957826 [No Abstract] [Full Text] [Related]
32. Face to face with lipoatrophy. An interview with David Nolan by Nelson Vergel. Nolan D GMHC Treat Issues; 2005; 19(3-4):1-6. PubMed ID: 16003843 [No Abstract] [Full Text] [Related]
33. Virammune and women in the news. Emery C Surviv News (Atlanta Ga); 2005; 16(2):10. PubMed ID: 16158512 [No Abstract] [Full Text] [Related]
34. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D; AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330 [TBL] [Abstract][Full Text] [Related]
35. New nevirapine label underscores the risk for hepatotoxicity in key populations. AIDS Clin Care; 2004 Mar; 16(3):24. PubMed ID: 15119295 [No Abstract] [Full Text] [Related]
36. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression. Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396 [TBL] [Abstract][Full Text] [Related]
37. Researchers find that Texas clinic's HIV resistance is stable over time. Clinic's population shifts to more Hispanics. AIDS Alert; 2007 Jan; 22(1):5-6. PubMed ID: 17722340 [No Abstract] [Full Text] [Related]
38. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384 [TBL] [Abstract][Full Text] [Related]
39. Antiretroviral drugs and the risk of myocardial infarction. Zangerle R; Sarcletti M N Engl J Med; 2007 Aug; 357(7):715-6; author reply 716-7. PubMed ID: 17703532 [No Abstract] [Full Text] [Related]
40. Warning against tenofovir + ddI + 3TC, and "triple nuke" combinations. AIDS Treat News; 2003 Oct; (395):2-3. PubMed ID: 14666910 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]